You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
The inhibitory effect of oxaprozin, a new non-steroidal anti-inflammatory drug, on platelet aggregation
|
|---|---|
| Published in |
Folia Pharmacologica Japonica, January 1984
|
| DOI | 10.1254/fpj.83.395 |
| Pubmed ID | |
| Authors |
GOTO Jun, Makoto MURAMATSU, Kazuaki HOSODA, Susumu OTOMO, Hironaka AIHARA |
| Abstract |
The inhibitory effects of oxaprozin, a new non-steroidal anti-inflammatory drug, on platelet aggregation and prostaglandin (PG) synthetase activity were studied. In arachidonic acid (AA)-induced rabbit platelet aggregation in vitro, oxaprozin exhibited a dose-dependent inhibitory effect, and its median inhibitory concentration was 124.2 microM. The effect of oxaprozin was less potent than that of indomethacin and piroxicam, equipotent as that of aspirin and phenylbutazone, and 2 times as potent as that of ibuprofen. In collagen-induced rat platelet aggregation ex vivo, oxaprozin showed a weak but significant inhibitory effect with oral dose of 300 mg/kg. Indomethacin, aspirin and ibuprofen exhibited an inhibitory effect with 100 mg/kg. Although phenylbutazone also exhibited an inhibitory effect with 300 mg/kg, the effect was more potent than that of oxaprozin. ADP-induced platelet aggregation both in rabbit in vitro and rat ex vivo was not affected by oxaprozin. Moreover, oxaprozin administered orally inhibited dose-dependently AA-induced pulmonary thrombotic mortality in mice, and its median effective dose was 56.4 mg/kg. The effect of oxaprozin was less potent than of sulindac, piroxicam and ibuprofen, equipotent as that of aspirin, and 5 times as potent as that of phenylbutazone. On the other hand, oxaprozin inhibited dose-dependently PG synthetase activity. The inhibitory effect of oxaprozin was less potent than that of indomethacin and piroxicam, almost equipotent as that of ibuprofen, and more potent than that of phenylbutazone and aspirin. These results suggest that oxaprozin, like many other acidic non-steroidal anti-inflammatory drugs, suppresses platelet aggregation by mainly inhibiting PG synthetase activity. |
Mendeley readers
The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 6 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor | 1 | 17% |
| Student > Ph. D. Student | 1 | 17% |
| Student > Bachelor | 1 | 17% |
| Other | 1 | 17% |
| Unknown | 2 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 2 | 33% |
| Chemistry | 1 | 17% |
| Immunology and Microbiology | 1 | 17% |
| Unknown | 2 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2014.
All research outputs
#8,534,528
of 25,371,288 outputs
Outputs from Folia Pharmacologica Japonica
#206
of 785 outputs
Outputs of similar age
#6,617
of 35,809 outputs
Outputs of similar age from Folia Pharmacologica Japonica
#2
of 16 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 785 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 35,809 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.